Logo image of GENE

Genetic Technologies Ltd (GENE) Stock Overview

USA - NASDAQ:GENE - US37185R4065 - ADR

0.765 USD
-0.02 (-1.92%)
Last: 10/16/2024, 9:36:40 PM
0.75 USD
-0.02 (-1.96%)
After Hours: 10/16/2024, 9:36:40 PM

GENE Key Statistics, Chart & Performance

Key Statistics
52 Week High3.77
52 Week Low0.67
Market Cap2.58M
Shares3.37M
Float242.36M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-2.74
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPO07-30 1987-07-30
Sector
GICS SectorHealth Care
GICS IndustryLife Sciences Tools & Services
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences


GENE short term performance overview.The bars show the price performance of GENE in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -20 -40 -60

GENE long term performance overview.The bars show the price performance of GENE in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of GENE is 0.765 USD. In the past month the price decreased by -3.89%. In the past year, price decreased by -79.19%.

Genetic Technologies Ltd / GENE Daily stock chart

GENE Latest News, Press Relases and Analysis

GENE Competitors/Peers

The largest stocks on the US markets in the "Life Sciences Tools & Services" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
TMO THERMO FISHER SCIENTIFIC INC 23.96 198.09B
DHR DANAHER CORP 27.24 146.89B
BRKRP BRUKER CORP - BRKR 6 3/8 09/01/28 134.42 43.85B
A AGILENT TECHNOLOGIES INC 25.36 39.19B
IQV IQVIA HOLDINGS INC 17.77 34.64B
MTD METTLER-TOLEDO INTERNATIONAL 31.41 26.47B
WAT WATERS CORP 27.5 20.02B
WST WEST PHARMACEUTICAL SERVICES 37.71 18.87B
TEM TEMPUS AI INC N/A 16.41B
MEDP MEDPACE HOLDINGS INC 39.21 14.81B
ILMN ILLUMINA INC 22.84 14.61B
ICLR ICON PLC 14.06 14.47B

About GENE

Company Profile

GENE logo image Genetic Technologies Ltd. operates as a molecular diagnostics company, which engages in the provision of molecular risk assessment tests for cancer. The company is headquartered in Melbourne, Victoria and currently employs 60 full-time employees. The firm is engaged in providing genomics-based tests on health, wellness and serious disease through its geneType and EasyDNA brands. The firm offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The firm has a proprietary risk stratification platform that integrates clinical and genetic risk to deliver outcomes to physicians and individuals. The firm operates through three segments: EasyDNA, AffinityDNA, and GeneType / Corporate. EasyDNA segment relates to EasyDNA branded test sales and expenses. AffinityDNA segment relates to AffinityDNA branded test sales and expenses. GeneType / Corporate segment relates to geneType branded test sales and expenses, including corporate charges. The GeneType test is for breast cancer, colorectal cancer, ovarian cancer, prostate cancer, coronary artery disease and mor

Company Info

Genetic Technologies Ltd

60-66 Hanover St, Fitzroy

Melbourne VICTORIA 3065 AU

CEO: Simon Morriss

Employees: 55

GENE Company Website

Phone: 61394151135

Genetic Technologies Ltd / GENE FAQ

What is the stock price of Genetic Technologies Ltd today?

The current stock price of GENE is 0.765 USD. The price decreased by -1.92% in the last trading session.


What is the ticker symbol for Genetic Technologies Ltd stock?

The exchange symbol of Genetic Technologies Ltd is GENE and it is listed on the Nasdaq exchange.


On which exchange is GENE stock listed?

GENE stock is listed on the Nasdaq exchange.


What is Genetic Technologies Ltd worth?

Genetic Technologies Ltd (GENE) has a market capitalization of 2.58M USD. This makes GENE a Nano Cap stock.


How many employees does Genetic Technologies Ltd have?

Genetic Technologies Ltd (GENE) currently has 55 employees.


What are the support and resistance levels for Genetic Technologies Ltd (GENE) stock?

Genetic Technologies Ltd (GENE) has a support level at 0.71 and a resistance level at 0.78. Check the full technical report for a detailed analysis of GENE support and resistance levels.


Should I buy Genetic Technologies Ltd (GENE) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does Genetic Technologies Ltd (GENE) stock pay dividends?

GENE does not pay a dividend.


What is the Price/Earnings (PE) ratio of Genetic Technologies Ltd (GENE)?

Genetic Technologies Ltd (GENE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.74).


GENE Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to GENE. When comparing the yearly performance of all stocks, GENE is a bad performer in the overall market: 93.77% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

GENE Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to GENE. GENE has a bad profitability rating. Also its financial health evaluation is rather negative.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

GENE Financial Highlights

Over the last trailing twelve months GENE reported a non-GAAP Earnings per Share(EPS) of -2.74. The EPS increased by 19.74% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -194.25%
ROE -656.53%
Debt/Equity 0.36
Chartmill High Growth Momentum
EPS Q2Q%34.06%
Sales Q2Q%-18.23%
EPS 1Y (TTM)19.74%
Revenue 1Y (TTM)-11.76%

GENE Forecast & Estimates


Analysts
Analysts0
Price TargetN/A
EPS Next YN/A
Revenue Next YearN/A

GENE Ownership

Ownership
Inst Owners2.68%
Ins OwnersN/A
Short Float %N/A
Short RatioN/A